Effectiveness and Safety of Direct-Acting Antivirals in the Treatment of Chronic Hepatitis C: A Real-life Study in Northeastern Brazil

Autor: Elodie Bomfim Hyppolito, Alberto Novaes Ramos Jr, Larissa Peixoto Teixeira, Arthur Machado Bezerra, Lucas Arruda Mendes, Taynara Lais Silva, José Milton de Castro Lima, Érico Antonio Gomes de Arruda, Eder Janes Guerra, Maria Macedo Saraiva Tavares, Carlos Eduardo Pereira Lima, Ticiana Mota Esmeraldo, Francisco Sérgio Rangel de Paula Pessoa, Alessandra Maria Montalverne Pierre, Karla Brandão Pereira, Antônio Haroldo Araújo Filho, Lívia Melo Carone Linhares, Anderson Fuentes Ferreira, Roberto da Justa Pires Neto
Jazyk: angličtina
Rok vydání: 2024
Předmět:
Zdroj: Revista da Sociedade Brasileira de Medicina Tropical, Vol 57 (2024)
Druh dokumentu: article
ISSN: 1678-9849
0037-8682
DOI: 10.1590/0037-8682-0192-2024
Popis: ABSTRACT Background: This study aimed to evaluate the effectiveness and safety of direct-acting antivirals (DAAs) for hepatitis C treatment by measuring sustained virologic response (SVR) and serious adverse events to help design effective interventions for reducing disease prevalence. Methods: This was a retrospective, observational, real-life study of patients with chronic hepatitis C receiving DAA treatment in the state of Ceará, Brazil. Data were collected in REDCap and analyzed using R® software by the Student's t, chi-square, and Fisher’s exact tests, with a significance level of 5%. Results: In this study, 1075 patients who were diagnosed with hepatitis C infection between October 2015 and October 2023 were included. The mean age of the participants was 56.6 ± 11 years and 60.2% were men. The sample included 51 HIV-infected patients (6.6%), 166 (15,4%) liver transplant recipients, 34 (3,1%) kidney transplant recipients, and 446 patients with cirrhosis (41.4%). The overall SVR rate was 96.4%. The sofosbuvir/daclatasvir/ribavirin regimen used in 354 (32.9%) patients achieved an SVR of 96%. The cure rate was 96.5%, with a lower SVR in patients with cirrhosis (93.4%) than in those with less severe fibrosis (97.9%) (p=0.0015). Serious adverse events associated with ribavirin use occurred in 3.5% of patients. Conclusions: DAA treatment for hepatitis C achieved SVR in real life in all patient profiles, including transplant recipients, HIV carriers, and patients with cirrhosis. Although these drugs are safe, a few decompensated patients with cirrhosis died during treatment.
Databáze: Directory of Open Access Journals
Externí odkaz: